SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-089787
Filing Date
2022-03-30
Accepted
2022-03-30 16:10:04
Documents
14
Period of Report
2022-03-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d339157d8k.htm   iXBRL 8-K 26655
2 EX-10.1 d339157dex101.htm EX-10.1 144562
6 GRAPHIC g339157sp020.jpg GRAPHIC 82692
  Complete submission text file 0001193125-22-089787.txt   442690

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA cue-20220328.xsd EX-101.SCH 2869
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cue-20220328_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cue-20220328_pre.xml EX-101.PRE 11268
8 EXTRACTED XBRL INSTANCE DOCUMENT d339157d8k_htm.xml XML 3331
Mailing Address 21 ERIE STREET CAMBRIDGE MA 02139
Business Address 21 ERIE STREET CAMBRIDGE MA 02139 617-949-2680
Cue Biopharma, Inc. (Filer) CIK: 0001645460 (see all company filings)

IRS No.: 473324577 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38327 | Film No.: 22786546
SIC: 2834 Pharmaceutical Preparations